Live Breaking News & Updates on Continuous Infusion

Stay updated with breaking news from Continuous infusion. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

No advantage of continuous vs intermittent meropenem in critically ill patients – the MERCY trial

1. The MERCY trial revealed that continuous infusion of meropenem does not confer a significant advantage over intermittent administration in reducing mortality and preventing new antibiotic-resistant bacteria in patients with either septic shock or sepsis. 2. This randomized control trial provides contrary evidence to previous systematic reviews and meta-analyses that found better outcomes with continuous ....

Intermittent Administration Of Meropenem , Rating Level , Continuous Infusion , Intermittent Administration , Critically Ill Patients , Simplified Acute Physiology Score , Septic Shock , Infectious Disease ,